scholarly journals Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors

2016 ◽  
Vol 25 (3) ◽  
pp. 739-748 ◽  
Author(s):  
Shah-Jalal Sarker ◽  
Sophia K. Smith ◽  
Kashfia Chowdhury ◽  
Patricia A. Ganz ◽  
Sheryl Zimmerman ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
The Impact ◽  
Lymphoma Survivors

Persistent fatigue among long-term non-Hodgkin lymphoma survivors

2021 ◽  
pp. 1-9
Author(s):  
Matthew R. LeBlanc ◽  
Sheryl Zimmerman ◽  
Thomas W. LeBlanc ◽  
Ashley Leak Bryant ◽  
Kathryn E. Hudson ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Persistent Fatigue ◽  
Lymphoma Survivors

scholarly journals Quality of Life Among Long-Term Survivors of Non-Hodgkin Lymphoma: A Follow-Up Study

2013 ◽  
Vol 31 (2) ◽  
pp. 272-279 ◽  
Author(s):  
Sophia K. Smith ◽  
Deborah K. Mayer ◽  
Sheryl Zimmerman ◽  
Christianna S. Williams ◽  
Habtamu Benecha ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Social Support ◽  
Hodgkin Lymphoma ◽  
Symptom Burden ◽  
Non Hodgkin Lymphoma ◽  
The Impact ◽  
Long Term Survivors ◽  
Over Time

Purpose Little is known about change in quality of life (QOL) among long-term cancer survivors. We examined change over time in QOL among long-term survivors of non-Hodgkin lymphoma and identified demographic, clinical, and psychosocial risk factors for poor outcomes. Methods Surveys were mailed to 682 lymphoma survivors who participated in a study 5 years earlier, when on average they were 10.4 years postdiagnosis. Standardized measures of QOL, perceptions of the impact of cancer, symptoms, medical history, and demographic variables were reported at both time points and examined using linear regression modeling to identify predictors of QOL over time. Results A total of 566 individuals participated (83% response rate) who were a mean of 15.3 years postdiagnosis; 52% were women, and 87% were white. One third of participants (32%) reported persistently high or improved QOL, yet a notable proportion (42%) reported persistently low or worsening QOL since the earlier survey. Participants who received only biologic systemic therapy reported improvement in physical health despite the passage of time. Older age, more comorbidity, and more or increasing negative and decreasing positive perceptions of cancer's impact were independent predictors of poor QOL. Lymphoma symptom burden, less social support, and having received a transplantation were related to negative perceptions of cancer's impact. Conclusion Moderate to severe symptom burden, limited social support, or having received a transplantation should alert the clinician to potential need for supportive services. Perceptions of cancer's impact are associated with QOL cross-sectionally and longitudinally; modifying these perceptions may thus provide a strategy for improving QOL.

scholarly journals OUTCOME AND TOXICITY PATTERNS IN CHILDREN AND ADOLESCENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

2018 ◽  
Vol 10 (1) ◽  
pp. e2018020 ◽  
Author(s):  
Paola Angelini ◽  
Laura Rodriguez ◽  
Mohammed Zolaly ◽  
Ahmed Naqvi ◽  
Sheila Weitzman ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Hodgkin Lymphoma ◽  
Survival Rates ◽  
Age At Diagnosis ◽  
Single Institution ◽  
Non Hodgkin Lymphoma ◽  
Sick Children ◽  
The Impact

Background: The incidence and biology of non-Hodgkin lymphoma (NHL) vary according to age. Some data suggest that the impact of age in pediatric and adolescent NHL patients depends on the histological subtype. Objectives: We aimed to analyze the impact of age at diagnosis on clinical characteristics and treatment-related toxicity in children and adolescents with NHL.Methods: Retrospective review of medical records of children and adolescents diagnosed with NHL at the Hospital for Sick children, Toronto, between January 1995 and December 2008.Results: 164 children were diagnosed with NHL during the study period, with a median age at diagnosis of 10 years. With a median follow-up of 6.2 years, 5-year OS in patients aged <15 and 15-18 years was 89± 2% vs 82% ± 6%, respectively (P = 0.30), and 5-year EFS was 84% ± 3% vs. 77% ± 7%  (P= 0.37). In Burkitts lymphoma (BL) and lymphoblastic lymphoma (LL) there was a trend towards better outcomes in children compared to adolescents, with EFS of  91% ± 4% vs. 75% ± 15%, respectively in BL (P= 0.17),  and 82% ± 7% vs. 51.4% ± 2% respectively in LL (P= 0.16). Late effects occurred in 21 patients (12.8%).Conclusions: Children with NHL aged < 15 years tend to have better survival rates and less long-term toxicity than adolescents aged 15-18 years.

Quality of life among long-term non-Hodgkin lymphoma survivors

Cancer ◽  
2007 ◽  
Vol 109 (8) ◽  
pp. 1659-1667 ◽  
Author(s):  
Floortje Mols ◽  
Neil K. Aaronson ◽  
Ad J. J. M. Vingerhoets ◽  
Jan-Willem W. Coebergh ◽  
Gerard Vreugdenhil ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Survivors

scholarly journals The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors

2010 ◽  
Vol 19 (12) ◽  
pp. 1259-1267 ◽  
Author(s):  
Sophia K. Smith ◽  
Catherine M. Crespi ◽  
Laura Petersen ◽  
Sheryl Zimmerman ◽  
Patricia A. Ganz
Keyword(s):  
Quality Of Life ◽  
Hodgkin Lymphoma ◽  
Post Treatment ◽  
Non Hodgkin Lymphoma ◽  
The Impact ◽  
Lymphoma Survivors

scholarly journals Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Raphaël Busson ◽  
Marleen van der Kaaij ◽  
Nicolas Mounier ◽  
Berthe M. P. Aleman ◽  
Catherine Thiéblemont ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Survivors

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3423-3423
Author(s):  
Amrita Krishnan ◽  
Andrew Raubitschek ◽  
Joycelynne Palmer ◽  
Auayporn P. Nademanee ◽  
N. Kogut ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
High Dose ◽  
Poor Risk ◽  
Non Hodgkin Lymphoma ◽  
The Impact

Abstract Abstract 3423 Poster Board III-311 Long term survival for patients with chemo-refractory non-Hodgkin lymphoma (NHL) is poor even with high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Strategies such as novel transplant conditioning regimens and post transplant maintenance therapy are being evaluated to improve outcomes. Herein we report on the results of a phase II study designed to assess the impact of a novel radioimmunotherapy (RIT) based conditioning regimen of Y90 ibritumomab tiuxetan in conjunction with high dose BEAM (BCNU, Etoposide, Ara–C, Melphalan) in patients with poor risk NHL. Between May 2002 and Jan 2009, 31 patients who were either primary induction failure (n=18) or in partial remission (n=13) underwent HDC with Y90 plus BEAM. Patients received an imaging dose of Indium 111 on day -21 followed by a treatment dose of Y90 (0.4mCi/kg) on day-14. HDC with BEAM was started on day -7. The median age at ASCT was 57 (range: 19–70). The majority of patients were male (n=23, 74%) and had advanced stage disease (III or IV) at the time of diagnosis, (n=23, 74%). The histologies included Follicular n=6, Diffuse Large B-cell n=13, Mantle cell n=8, and Transformed n=4. The median number of prior regimens was 2 (range: 1-5). All patients engrafted at a median of 11 days. At the time of analysis, 23 (74%) patients were alive, and eight had expired (seven due to relapse/progressive disease, one due to COPD). The non-relapse mortality was 3.2%. The median length of follow-up for surviving patients is 46.9 months (range: 3.3-75.0). The two-year overall survival and disease-free survival was 77.9% (95%CI: 62.7-87.6%) and 50.9% (95%CI: 40.5-60.3%) respectively for the entire cohort. However, the relapse rate in the subset of MCL pts was strikingly high and approached 80% at 4 yrs. The other subgroups had a stable DFS (figure 1). In conclusion in this poor risk group of patients Y90 plus high dose BEAM can induce responses and long term remissions, however, for patients with chemorefractory MCL other treatment approaches may be warranted. Disclosures Off Label Use: yttrium 90 in combination with high dose BEAM chemotherapy.

Fatigue in long-term non-Hodgkin lymphoma survivors.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20628-e20628
Author(s):  
Kathryn Elizabeth Hudson ◽  
Habtamu Kassa Benecha ◽  
Kevin Leo Houck ◽  
Thomas William LeBlanc ◽  
Amy Pickar Abernethy ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Lymphoma Survivors

scholarly journals Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study

2012 ◽  
Vol 22 (6) ◽  
pp. 1258-1265 ◽  
Author(s):  
Simone Oerlemans ◽  
Sophia K. Smith ◽  
Catherine M. Crespi ◽  
Sheryl Zimmerman ◽  
Lonneke V. van de Poll-Franse ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
National Study ◽  
Non Hodgkin Lymphoma ◽  
Cross National Study ◽  
The Impact ◽  
Lymphoma Survivors ◽  
Cross National
Sign in / Sign up

Export Citation Format

Share Document